Active Ingredient: Tirzepatide
Dosage form: Subcutaneous injection solution
Medication frequency: Once a week. Each dose contains 4 vials of injectable medication, sufficient for four weeks of use.
Brand Name: Mounjaro
Generic name: Tizaro
Generic drug manufacturer: Zisk Pharmaceuticals
Indications:
Tirzepatide is a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is indicated for the treatment of type 2 diabetes and obesity, as an adjunct to diet and exercise to improve glycemic control and weight management.
Dosage and Usage:
Subcutaneous injection once weekly. Tirzepatide is available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The starting dose is 2.5 mg weekly, maintained for 4 weeks. If no adverse reactions occur, the dose can be sequentially escalated to the next level, with each dose maintained for 4 weeks, and the maximum dose is 15 mg weekly. If a dose is missed, it should be administered within 96 hours; otherwise, skip the missed dose and continue according to the original schedule. Injection sites include subcutaneous fat in the abdomen, thighs, and upper arms, with rotation of injection sites required.
Side effects:
Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. Similar to other GLP-1 receptor agonists, some patients may experience individual variation in response.
Storage conditions:
Store in a refrigerator at 2°C to 8°C. Do not freeze. Avoid light exposure and keep out of reach of children.
Transportation Instructions:
Tirzepatide can be stored at room temperature for up to 21 days. The product is shipped directly by the manufacturer and can be delivered via air transport in approximately one week. It can be stored at room temperature during transit without affecting efficacy. Please use it with confidence.
Common Questions:
Q: Is the Tirzepatide injection sold by Drug God's Direct Delivery a branded drug?
A: No. The drugs sold by Yashu are generic medications produced by the top ten pharmaceutical manufacturers in Bangladesh, containing the same active ingredients and efficacy as the brand-name drugs. They have passed inspections by the Drug General Administration (DGDA) and are legally registered and marketed locally.
Q: Is the pharmaceutical company producing tirzepatide reliable?
A: The pharmaceutical company we collaborate with is Ziska Pharmaceuticals, one of the top ten pharmaceutical manufacturers in Bangladesh, equipped with R&D, production, and quality control laboratories, and certified with international pharmaceutical production quality standards.
Q: How should Tirzepatide be administered? How often should it be injected? Is the injection painful?
A: Tirzepatide is available as a subcutaneous injection, administered once weekly. It should be self-injected into the subcutaneous fat of the abdomen, thigh, or upper arm, with a recommended fixed time for injection and weekly rotation of injection sites. Most patients experience minimal pain during administration.
Q: Which has better weight loss effects, tirzepatide or semaglutide?
A: According to the SURMOUNT-5 Phase 3 clinical trial by Eli Lilly, tirzepatide demonstrated superior weight loss efficacy compared to semaglutide. Over the 72-week trial period, tirzepatide achieved an average weight loss of 20.2% (approximately 22.8 kg), while semaglutide resulted in an average weight loss of 13.7% (approximately 15.0 kg).
Q: Which has milder side effects, tirzepatide or semaglutide?
A: The common side effects of both are gastrointestinal reactions (nausea, bloating, diarrhea, constipation), which are usually more pronounced in the early stages of treatment or when the dosage is increased and tend to subside over time. Some patients report milder side effects when using tirzepatide.
Disclaimer:
This information is for reference only. Specific treatment choices should be followed under the guidance of a physician, with reference to the drug instructions and the latest research.